KalVista Pharmaceuticals announced the UK Medicines and Healthcare products Regulatory Agency has awarded the Promising Innovative Medicine designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. The PIM is the first step in the Early Access to Medicines Scheme which would allow KalVista to treat patients with sebetralstat prior to receiving a Marketing Authorisation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KALV:
- KalVista Pharmaceuticals Announces Executive Leadership Transition
- KalVista appoints Benjamin Palleiko as CEO
- KalVista presents additional Phase 3 KONFIDENT data at AAAAI meeting
- KalVista awarded UK Innovation Passport for sebetralstat
- KalVista Pharmaceuticals Secures Funding to Advance Clinical Programs
